Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced ovarian cancer with positive BRCA1 or BRCA2 status~* Progressive or recurrent disease after platinum-based chemotherapy~* Measurable disease by RECIST~Exclusion Criteria:~* Previous anthracycline treatment~* Brain metastases~* Less than 28 days since last treatment used to treat the disease~* Considered a poor medical risk due to a serious uncontrolled disorder

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD2281 Oral 200 mg BID
- 2 (Type: ACTIVE_COMPARATOR): Liposomal Doxorubicin
- 3 (Type: EXPERIMENTAL): AZD2281 Oral 400 mg BID

Based on this trial design, predict the completion outcome and termination type (if applicable).